Genetically informed drug development and repurposing is an attractive prospect for
improving patient outcomes in psychiatry; however, the effectiveness of these endeavors is …

Using successful genome-wide association results in psychiatry for drug repurposing is an
ongoing challenge. Databases collecting drug targets and gene annotations are growing …

Importance Psychiatric disorders display high levels of comorbidity and genetic overlap,
necessitating multivariate approaches for parsing convergent and divergent psychiatric risk …

Individuals with complex disorders typically have a heritable burden of common variation
that can be expressed as a polygenic risk score (PRS). While PRS has some predictive …

Genome-wide association studies (GWAS) have identified thousands of novel genetic
associations for complex genetic disorders, leading to the identification of potential …

Human genetics is a rational starting point for target identification in drug discovery, yet this
approach has found little application in neuroscience. Recent large-scale analyses have …

Using successful genome-wide association results in psychiatry for drug repurposing is an
ongoing challenge. Databases collecting drug targets and gene annotations are growing …

There have been no new drugs for the treatment of schizophrenia in several decades and
treatment resistance represents a major unmet clinical need. The drugs that exist are based …

Abstract Knowledge of psychiatric disease genetics has advanced rapidly during the past
decade with the advent of genome-wide association studies (GWAS). However, less …

Schizophrenia is an often devastating neuropsychiatric illness. Understanding the genetic
variation affecting response to antipsychotics is important to develop novel diagnostic tests …